Profound Medical Corp. (TSE:PRN) Director Buys C$143,319.75 in Stock

Profound Medical Corp. (TSE:PRN) Director Arun Menawat Dr. bought 14,200 shares of the company’s stock in a transaction dated Friday, March 14th. The stock was purchased at an average price of C$10.09 per share, for a total transaction of C$143,319.75.

Profound Medical Trading Down 3.6 %

Shares of TSE PRN opened at C$9.67 on Friday. The firm’s 50 day moving average price is C$9.84 and its 200-day moving average price is C$10.46. The company has a market cap of C$203.77 million, a PE ratio of -5.02 and a beta of 0.81. Profound Medical Corp. has a 52-week low of C$7.90 and a 52-week high of C$15.75. The company has a debt-to-equity ratio of 20.05, a quick ratio of 14.98 and a current ratio of 6.12.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.